Europlasma’s technology creates a stable and effective plasma by an electromagnetic discharge of a process gas at low pressure (and low temperature).

Historically, this technology was mainly used for ultra-fine cleaning, for etching or for physical and chemical activation of surfaces. Europlasma has been among the first to use the technology to apply ultra-thin coatings on surfaces by using more complex process chemicals. This requires a deep knowledge of plasma technology, process chemistry, material sciences and vacuum equipment design.

With low pressure plasma technology, the ultra-thin coating is applied uniformly on complex three dimensional surfaces, and it can penetrate into the core of complex shaped materials or products such as PCB’s, electronic devices, filtration membranes or technical textiles.

The unique way in which the coatings are deposited allows to achieve outstanding functional performance. At the same these coatings are so thin that they are not visible and do not alter the other characteristics of your products.

Through more than twenty two years of experience with low pressure plasma technology, Europlasma has been able to optimize this process to an industrial scale, unmatched in the industry.

Key technical advantages in coating electronics
• Uniform coverage of complex three dimensional surfaces
• Penetration into core of complex shaped products
• No change in colour
• No impact on acoustic behaviour or good working of micro devices
• Coatings have z-axis conductivity
• Coatings are easy to rework
• Dry and clean production process

Europlasma’s coatings are ultra-thin, z-axis conductive and do not require masking of the electrical contact points, unlike alternative technologies. This allows for a fast and flexible production process that can be applied on an industrial scale at an acceptable cost.

As part of the diagnostic workup, patients typically undergo cognitive testing, basic laboratory testing and brain magnetic resonance imaging (MRI). Additional testing is often performed depending on the suspected cause of symptoms, such as biomarkers from cerebrospinal fluid (CSF), positron emission tomography (PET) imaging or comprehensive neuropsychological assessment.

It goes without saying that reviewing all this multisource data, and mentally picturing whether single tests or combination of tests points to a certain diagnosis, is a daunting task. It is further complicated by the fact that there are multiple possible diagnoses and other reasons (or diseases) that may cause the symptoms of the patient. The relative importance of single tests or biomarkers depends on which diagnosis is being considered. The interpretation of test results depends also on background factors, such as the patient’s age. Finally, economic constraints may define which tests are available and afforded.

To help overcome the difficulties in dementia diagnosis, Combinostics has developed cNeuro®, a cloud-based software tool with the modules cMRI for advanced image analytics and cDSI for data-driven clinical decision support.

cNeuro® cMRI provides fully automated quantification of MRI T1 and FLAIR images. Based on T1 brain images, cMRI computes volumes of 102 cortical parcellations and 31 subcortical structures. Extracted volumes are compared to a normative database and percentiles are computed. Based on FLAIR images, cMRI segments white matter hyperintensities (WMH) and results are compared to a normative WMH database.

In addition to the volumes of structures and WMHs, cMRI computes specific dementia related imaging biomarkers. An anterior-posterior index is used to compare atrophy in the anterior versus the posterior parts of the brain and has been shown to be useful for differentiating AD from FTD. Furthermore, cMRI provides computed MTA, GCA (global & lobes) and Fazekas scales. There are several advantages of the computed scales over the visual scoring scales; the computed scales are objective, they use a continuous scale and they are compared to normative data.

All quantitative information is corrected for age, gender and head size. cMRI provides interactive review of images with the ability to toggle segmentation overlays on/off. cMRI generates an “Atrophy and lesion” PDF report including report of longitudinal change.

cNeuro® cMRI is a CE marked and FDA 510(k) cleared product that helps radiologist provide high quality reporting in shorter time.

cNeuro® cMRI is a product on its own, providing information about how a patient’s images differ from what is expected in an age and gender matched healthy individual. However, for the neurologist, imaging information is just one piece of the puzzle. Furthermore, the neurologist is not primarily interested in whether the patient differs from normal or not, but what the underlying disease is. This is where cDSI comes in.

cDSI is a machine learning system that has been trained with data from a large number of previously diagnosed patients where diagnosis is confirmed through longitudinal follow up. Data sources supported include imaging biomarkers from cMRI, various clinical and neuropsychological tests, as well as CSF biomarkers and APOE status. cDSI compares the data from the patient being evaluated with all previous data, and for each biomarker or test result, a disease state index (DSI) is computed measuring the similarity of the patient to previously diagnosed patients. Results from different tests are then combined in a hierarchical way producing one DSI that represents all data combined. cDSI provides two decision models, etiology and progression. The etiology model presents information about which underlying etiology is the most likely. Supported etiologies include AD, FTD, VaD and cognitive normal (CN). The progression model compares the patient’s data to data from sMCI and pMCI and provides information about similarity of an MCI patient to one of these two groups.

A graphical tree structure, called the disease state fingerprint (DSF) visualizes how each test or biomarker contributes to the overall DSI result. This allows the clinician to, with one glance, see how different test results or groups of test results affect the patient’s similarity to a certain disease. This transparency of the system is critical for acceptance of these types of tools in clinical routine.

In summary cNeuro® cDSI is a CE marked tool intended for the diagnosing clinician and it helps clinical decision making by providing an explicit comparison of the patient’s data to data from previous patients, both on the single biomarker level, on an intermediate level and on a level with all data combined.